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Background/introduction
Fibroadenomas are common, benign lesions of the
breast. A minority of fibroadenomas will disappear with-
out treatment, but most increase in size or remain
unchanged. Current management of patients with
fibroadenomas in the United States varies on a case by
case basis and includes observation or surgical excision.
Many patients find their fibroadenoma bothersome, and
opt for surgical excision. The objectives of this study are
to evaluate the safety and feasibility of Ultrasound
guided High Intensity Focused Ultrasound (USgHIFU)
delivered by the Echopulse device (Theraclion, Paris) for
treatment of breast fibroadenomas. General patient
safety, cosmetic outcome, tumor response, patient
experience, physician/operator experience, and device
performance will be assessed.
Methods
Twenty female patients diagnosed with palpable, non-cal-
cified breast fibroadenomas 1cm or larger will be enrolled
in a single arm clinical trial and undergo treatment of
their tumor utilizing a computer-driven, continuously
cooled, extra-corporal HIFU probe mounted on an arm
moved by motors, and guided in real-time with an inte-
grated ultrasound imaging scanner. The integrated probe
is positioned by the operator and the lesion is imaged.
Treatment planning is automated and presented for
review and approval on an integrated computer screen.
Optimal energy per sonication is established for each
patient by determining the minimal setting found to pro-
duce bubbles within the lesion as observed on real-time
B-mode ultrasound. Patients will have tumors meeting
the following criteria: Distance from the skin of ≤ 23 mm
to the posterior border of the fibroadenoma, ≥ 5 mm
from the anterior border of the fibroadenoma, and ≥
11mm from the focal point of the HIFU treatment. The
chest wall must be more than 1cm from the posterior
margin of the tumor, and tumor volume must be
between 0.3cc and 10cc.
Results and conclusions
Subjects will be evaluated immediately after treatment
and at 3, 6, and 12 months. Primary endpoints assessed
will include:
• Palpability of breast lesion at 12 months following
HIFU treatment session
• Patient-rated pain of the HIFU treatment assessed
after completion of the treatment session
• Patient satisfaction at 3, 6 and 12 months following
HIFU treatment session
• Change in volume of the fibroadenoma compared to
baseline at 3, 6 and 12 months after the IFU session as
assessed by ultrasound
Secondary endpoints assessed will include:
• Palpability of breast lesion at 3 and 6 months following
HIFU treatment session
• Cosmetic evaluation at 3, 6 and 12 months following
HIFU treatment session
• Investigator-rated evaluation of the device
• Incidence of local and/or general adverse events
and other associated symptoms at 3, 6 and 12 months
follow-up
• Treatment parameters including duration of the
treatment session and device energy settings
• The IDE application for this study has been approved,
and the trial is under accrual.
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Figure 1 Minimum Tumor Criteria
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